Genomics News and Research

RSS

Genomics is the study of the complete genetic material, including genes and their functions, of an organism.

Favorable results from CytRx’s INNO-206 Phase 1b/2 trial on soft tissue sarcomas

CytRx Corporation, a biopharmaceutical company specializing in oncology, announces that favorable clinical results from its Phase 1b/2 clinical trial with its tumor-targeting doxorubicin conjugate INNO-206 in patients with advanced solid tumors, primarily soft tissue sarcomas, are being presented today at the American Society of Clinical Oncology (ASCO) conference in Chicago.

4 Jun 2012

Promega launches novel luciferase more versatile than current bioluminescent enzyme

Promega Corporation announces the launch of a novel luciferase that is smaller, brighter, and more versatile than any current bioluminescent enzyme. These attributes of the NanoLuc Luciferase provide new capabilities in reporter assays with potential in biologically complex applications that require greater sensitivity.

1 Jun 2012

Personalized medicine and the Human Genome Project

It’s nearly a decade since the completion of the Human Genome Project, (1) which aimed to sequence the complete human genome.

1 Jun 2012

N-of-One develops unique knowledge integration platform for oncologists

N-of-One, Inc., provider of Diagnostic Strategy Roadmaps and Treatment Strategy Roadmaps for personalized cancer care, announced today that the company has developed a unique knowledge integration platform to enable care providers and patients to make informed decisions about diagnostic and treatment strategy.

1 Jun 2012

Illumina launches Nextera XT DNA Sample Preparation Kits

Illumina today introduced the Nextera XT DNA Sample Preparation Kit, the easiest way for researchers to prepare and sequence small genomes, PCR amplicons, and plasmids.

From Illumina, Inc. 1 Jun 2012

ForteBio introduces new biosensor for use on Octet and BLItz instrumentation platforms

ForteBio, a division of Pall Life Sciences and a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the introduction of its Dip and Read Ni-NTA biosensor for use on its Octet and BLItz instrumentation platforms.

1 Jun 2012

Life Technologies, OpGen enter collaboration on Whole Genome Mapping and Ion Torrent sequencing

Life Technologies Corporation and OpGen, Inc., a commercial stage whole genome analysis company, today announced that they have signed a collaboration agreement to develop systems, technologies and applications intended to improve the management and surveillance of microbial outbreaks in the public health and infectious disease markets.

31 May 2012

Foundation Medicine introduces first pan-cancer genomic profile

Foundation Medicine announced today the commercial launch of FoundationOne, the first pan-cancer, fully informative genomic profile designed to help oncologists expand their patients' treatment options.

31 May 2012

Omixon Target, a next generation sequencing analysis software for targeted sequencing, released by Omixon

Today Omixon – a genomic software company - announced the commercial release of Omixon Target, a next generation sequencing analysis software for targeted sequencing. Omixon built its new software Target with the vision of helping diagnostic labs to adopt next generation sequencing to replace and complement traditional capillary Sanger sequencing.

30 May 2012

Nature Genetics publishes results from whole genome-wide study of recurrent HBV integration in HCC

The Asian Cancer Research Group (ACRG)—an independent, not-for-profit company established by Eli Lilly and Company, Merck (known as MSD outside the United States and Canada) and Pfizer Inc.—in collaboration with BGI—the world's largest genomics organization—today announced the publication of results from a whole genome-wide study of recurrent hepatitis B virus (HBV) integration in hepatocellular carcinoma (HCC) in Nature Genetics.

30 May 2012

QCMG establishes Illumina technology as core sequencing platform

Illumina today announced that the Queensland Centre for Medical Genomics (QCMG), home of Australia's International Cancer Genomics Consortium program, has established Illumina technology as its core sequencing platform in an expanded facility.

30 May 2012

Researchers develop tentative model for diagnosis of colon cancer

Researchers from the Universidad Politécnica de Madrid's Facultad de Informática, the Universidad del País Vasco, the Gaiker Technology Centre (Biscay) and the Hospital de Cruces in Barakaldo, have developed a tentative model for the diagnosis of colon cancer based on a biomarker panel.

28 May 2012

UCLA geneticists identify mutation responsible for IMAGe syndrome

UCLA geneticists have identified the mutation responsible for IMAGe syndrome, a rare disorder that stunts infants' growth. The twist? The mutation occurs on the same gene that causes Beckwith-Wiedemann syndrome, which makes cells grow too fast, leading to very large children.

28 May 2012

BBSRC allocates £250M for strategic investment programmes

Minister for Universities and Science, David Willetts, will today announce substantial funding that will ensure the UK's bioscience research base remains globally competitive and at the forefront of meeting the grand challenges faced by society in the coming decades. The announcement will be made by the Minister during a visit to the Babraham Research Campus, near Cambridge, and highlighted again during a major speech at the University of East Anglia in Norwich.

25 May 2012

EPSRC to help researchers in synthetic biology to establish platform technology

The Engineering and Physical Sciences Research Council (EPSRC) will help the UK's world-leading researchers in synthetic biology to establish platform technology in the emerging field with a new grant of almost -5 million. Platform technology is the crucial next step necessary for applications to be produced and commercialised.

25 May 2012

Study shows how chromosomal mutation likely contributes to early development of prostate cancer

Up to half of all prostate cancer cells have a chromosomal rearrangement that results in a new "fusion" gene and formation of its unique protein -- but no one has known how that alteration promotes cancer growth. Now, Weill Cornell Medical College researchers have found that in these cancer cells, the 3-D architecture of DNA, wrapped up in a little ball known as a chromatin, is warped in such a way that a switch has been thrown on thousands of genes, turning them on or off to promote abnormal, unchecked growth. Researchers also found that new chromosomal translocations form, further destabilizing the genome.

23 May 2012

Scientists determine genetic sequences of all 12 vancomycin-resistant staph strains

National Institutes of Health-funded scientists have determined the genetic sequences of all 12 available strains of Staphylococcus aureus bacteria resistant to vancomycin-an antibiotic of last resort-and have demonstrated that resistance arose independently in each strain after it acquired a specific bit of genetic material called transposon Tn1546

23 May 2012

Scientists trace origin and development of vancomycin-resistant S. aureus

National Institutes of Health-funded scientists have determined the genome sequences of a dozen strains of Staphylococcus aureus bacteria known to be resistant to vancomycin, an antibiotic of last resort. The researchers demonstrated -that resistance arose independently in each strain, and identified shared features among the strains that may have helped them acquire vancomycin resistance and evade human immune defenses.

23 May 2012

Researcher restructures innovative virus-tracking software

A biomedical informatics researcher who tracks dangerous viruses as they spread around the globe has restructured his innovative tracking software to promote even wider use of the program around the world.

23 May 2012

NIEHS renews funding for SRP at UCSD

The National Institute of Environmental Health Sciences (NIEHS), part of the National Institutes of Health, has renewed funding for the Superfund Research Program (SRP) at the University of California, San Diego. Over the next five years, the $15 million grant will fund continued research on the molecular and genetic consequences of exposure to uncontrolled toxicants from Superfund and other hazardous waste sites.

23 May 2012

Genomics News and Research

Further Reading

Favorable results from CytRx’s INNO-206 Phase 1b/2 trial on soft tissue sarcomas

Promega launches novel luciferase more versatile than current bioluminescent enzyme

Personalized medicine and the Human Genome Project

N-of-One develops unique knowledge integration platform for oncologists

Illumina launches Nextera XT DNA Sample Preparation Kits

ForteBio introduces new biosensor for use on Octet and BLItz instrumentation platforms

Life Technologies, OpGen enter collaboration on Whole Genome Mapping and Ion Torrent sequencing

Foundation Medicine introduces first pan-cancer genomic profile

Omixon Target, a next generation sequencing analysis software for targeted sequencing, released by Omixon

Nature Genetics publishes results from whole genome-wide study of recurrent HBV integration in HCC

QCMG establishes Illumina technology as core sequencing platform

Researchers develop tentative model for diagnosis of colon cancer

UCLA geneticists identify mutation responsible for IMAGe syndrome

BBSRC allocates £250M for strategic investment programmes

EPSRC to help researchers in synthetic biology to establish platform technology

Study shows how chromosomal mutation likely contributes to early development of prostate cancer

Scientists determine genetic sequences of all 12 vancomycin-resistant staph strains

Scientists trace origin and development of vancomycin-resistant S. aureus

Researcher restructures innovative virus-tracking software

NIEHS renews funding for SRP at UCSD

Genetics & Genomics - Second Edition eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News